Search

Hemangioma of the nasal tip is commonly described as “Cyrano nose” and his treatment is extremely difficult because of its location and possible severe aesthetic complications like definitive nasal deformation. We describe a patient who presented at two months of age with a “Cyrano nose” associated with multiple hepatic and cutaneous hemangiomas, which completely resolved after therapy with propranolol. Treatment was well tolerated and aesthetic result was excellent.

Acute events in children with sickle cell disease in Italy during the COVID-19 pandemic: useful lessons learned Acute chest, children, COVID-19, Italy, sickle cell disease, Vaso-occlusive crisis Keywords: acute chest; children; COVID-19; Italy; sickle cell disease; Vaso-occlusive crisis EN acute chest children COVID-19 Italy sickle cell disease Vaso-occlusive crisis 851 854 4 09/02/21 20210901 NES 210901 On March 12th 2021 the Italian Government decided to implement a national lockdown in almost all the regions of the country. [Extracted from the article]

Objectives: HbS/β+ patients' presence in Italy increased due to immigration; these patients are clinically heterogeneous, and specific guidelines are lacking. Our aim is to describe a cohort of HbS/β+ patients, with genotype‐phenotype correlation, in order to offer guidance for clinical management of such patients. Methods: Retrospective cohort study of HbS/β+ patients among 15 AIEOP Centres. Results: A total of 41 molecularly confirmed S/β+ patients were enrolled (1‐55 years, median 10.9) and classified on β+ mutation: IVS‐I‐110, IVS‐I‐6, promoter, and "others." Prediagnostic events included VOC 16/41 (39%), ACS 6/41 (14.6%), sepsis 3/41 (3.7%), and avascular necrosis 3/41 (7,3%). Postdiagnostic events were VOC 22/41 (53.6% %), sepsis 4/41 (9.7%), ACS 4/41 (9.7%), avascular necrosis 3/41 (7.3%), aplastic crisis 2/41 (4.8%), stroke 1/41 (2.4%), ACS 1/41 (2.4%), and skin ulcerations 1/41 (2.4%). The IVS‐I‐110 group presented the lowest median age at first SCD‐related event (P =.02 vs promoter group) and the higher median number of severe events/year (0.26 events/patient/year) (P =.01 vs IVS‐I‐6 and promoter groups). Promoter group presented a specific skeletal phenotype. Treatment regimen applied was variable among the centers. Conclusions: HbS/β+ is not always a mild disease. Patients with IVS‐I‐110 mutation could benefit from a standard of care like SS and S/β° patients. Standardization of treatment is needed. [ABSTRACT FROM AUTHOR]